Cannabis Law Report

JUNE 7, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. About MyMD Pharmaceuticals, Inc. MyMD is a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms. blocking drugs, and aging and longevity.

Pharmaceutical 79

Pharmaceutical Clinical Trials CBD Banking 79

Project CBD

JULY 31, 2018

With Congress seemingly poised to legalize the cultivation of industrial hemp for many uses, including the production of biomass for CBD oil extraction, many questions remain unanswered. How will the DEA reschedule CBD now that Epidiolex has been approved as a pharmaceutical CBD isolate?

Hemp 203

Hemp CBD DEA Pharmaceutical 203

MMJ Recs

APRIL 1, 2024

In recent years, the spotlight on CBD (cannabidiol) within medical marijuana has intensified, with researchers and medical professionals delving deeper into its potential therapeutic benefits. CBD, one of the many cannabinoids found in the cannabis plant, has been garnering attention for its promising effects on various health conditions.

CBD 52

CBD Clinical Trials Chronic Pain Epilepsy 52

Cannabis Law Report

MAY 31, 2023

MGC Pharmaceuticals Ltd (LSE:MXC, OTC:MGCLF, ASX:MXC) has passed a significant milestone, delivering the first doses of its CannEpil® units to patients in the United Kingdom, paving the way for the treatment of refractory epilepsy, an unmet need in the country.

Epilepsy 52

Epilepsy Pharmaceutical Treatment Patients 52

Medical Marijuana Program Connection

MARCH 2, 2023

MyMD Pharmaceuticals, Inc. MYMD announced that the U.S. Drug Enforcement Administration has conducted a scientific review and determined that investigational. Read More

Pharmaceutical 52

Pharmaceutical DEA CBD 52

Veriheal

AUGUST 12, 2021

million people across the United States , report experiencing improved quality of life and a more restful night’s sleep after consuming the non-psychoactive cannabinoid CBD (cannabidiol). CBD, which constitutes a $2,770.8 CBD, which constitutes a $2,770.8 What is Artisanal CBD? It goes by the name of “artisanal CBD.” .

Epilepsy 68

Epilepsy Pharmaceutical Patients Sleep 68

Cannabis Law Report

APRIL 28, 2021

Poster presentation to address the preclinical cannabidiol derivative for the potential treatment of psychiatric disorders BALTIMORE–(BUSINESS WIRE)–MyMD Pharmaceuticals, Inc. Nasdaq:… Read More.

Pharmaceutical 98

Pharmaceutical Data Medicine Treatment 98

Cannabis Law Report

SEPTEMBER 22, 2021

New data will be presented at the 4th Annual International Cannabinoid-Derived Pharmaceuticals Summit in Boston. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. A vast majority of CBD developers are pursuing compounds targeted to CB2 that have minimal CB1 affinity. Watch how Supera-CBD works. “We

Pharmaceutical 52

Pharmaceutical Data CBD Clinical Trials 52

Cannabis Law Report

JULY 7, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. About MyMD Pharmaceuticals, Inc. MyMD is a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms. Eurofins is a global leader in food, environment, and pharmaceutical product testing.

Pharmaceutical 105

Pharmaceutical Data Clinical Trials Research and Development 105

Cannabis Law Report

FEBRUARY 23, 2022

(TSX: LABS) (OTCQX: MEDIF ) (FSE: MLZ) (“MediPharm” or the “Company”) a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it has completed a US FDA DMF for pure natural CBD API. These projects will all require pharmaceutical approved API if commercialized. Management Commentary.

Pharmaceutical 52

Pharmaceutical Research and Development Extraction Cannabinoids 52

Cannabis Law Report

DECEMBER 15, 2021

Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (NASDAQ: CGC ) has entered into an agreement to divest its subsidiary business, C³ Cannabinoid Compound Company GmbH (“C3”), to Dermapharm Holding SE (“Dermapharm”) (WKN: A2GS5D, ISIN: DE000A2GS5D8), a European pharmaceutical company headquartered in Grünwald, Germany.

Pharmaceutical 52

Pharmaceutical Cannabinoids Business Extraction 52

Cannabis Law Report

AUGUST 24, 2021

BALTIMORE–(BUSINESS WIRE)– $MYMD — MyMD Pharmaceuticals, Inc. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc. The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy. For more information, visit www.mymd.com.

Pharmaceutical 98

Pharmaceutical Clinical Trials Chronic Pain CBD 98

Project CBD

MAY 1, 2019

Conventional pharmaceuticals commonly used to treat pain sometimes have a negative impact on the immune system, GI tract, liver, and kidneys. The state of veterinary medicine has advanced significantly in recent years and thanks to the availability of more effective medicine, many pets are living longer than they would have years ago.

Pets 257

Pets Pharmaceutical CBD Medicine 257

Project CBD

DECEMBER 5, 2019

Life-threatening side effects from pharmaceuticals led one man to try cannabis. In this testimonial, he shares how cannabis helped him overcome refractory lockjaw and severe nerve pain.

Nerve Pain 234

Nerve Pain Pharmaceutical CBD Cannabis 234

Project CBD

JULY 28, 2023

Project CBD: Your presentation with Allyn Howlett at the International Cannabinoid Research Society conference in Toronto (June 2023) discussed the chemical conversion of CBD into Δ8-THC (delta-8 THC) and “numerous additional THC isomers. Scialdone: Only Δ8, Δ9, and Δ10 THC can be synthesized from hemp-derived CBD.

THC 212

THC Cannabinoids Hemp Research and Development 212

Cannabis Law Report

SEPTEMBER 9, 2021

MyMD to highlight its development pipeline for MYMD-1, an immunometabolic regulator, and Supera-CBD, a synthetic cannabidiol derivative. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc. For more information, visit www.mymd.com.

Pharmaceutical 97

Pharmaceutical Clinical Trials Chronic Pain Epilepsy 97

Leafwell

MAY 10, 2021

For many people interested in cannabis as medicine CBD oil provides an option to try medical marijuana while avoiding the psychoactive effects of THC. The hemp and CBD industries are growing exponentially every year as more people turn away from pharmaceuticals in search of a natural alternative: enter CBD.

Oil 90

Oil CBD Pharmaceutical Hemp 90

Leafwell

MAY 10, 2021

For many people interested in cannabis as medicine CBD oil provides an option to try medical marijuana while avoiding the psychoactive effects of THC. The hemp and CBD industries are growing exponentially every year as more people turn away from pharmaceuticals in search of a natural alternative: enter CBD.

Oil 90

Oil CBD Pharmaceutical Hemp 90

Cannabis Law Report

AUGUST 10, 2021

We are delighted by today’s decision from the MHRA for this new indication, which represents a significant step forward for TSC patients in the UK, many of whom may benefit from this new treatment,” said Chris Tovey , Executive Vice President, Chief Operating Officer and Managing Director, Europe & International at Jazz Pharmaceuticals.

Pharmaceutical 98

Pharmaceutical Treatment Epilepsy Research and Development 98

The Fresh Toast

DECEMBER 21, 2021

THC More Effective Than CBD In Treating Autism, New Preliminary Study Shows. As cannabis becomes less stigmatized, the autism community is exploring treatments that are more accessible and less pharmaceutical. The post THC More Effective Than CBD In Treating Autism, New Preliminary Study Shows appeared first on The Fresh Toast.

THC 105

THC CBD Pharmaceutical Treatment 105

Cannabis Law Report

DECEMBER 1, 2021

MyMD to highlight its development pipeline for two novel therapeutics: immune regulator MYMD-1 and synthetic cannabidiol derivative Supera-CBD. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. About Supera-CBD. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc. Livestream: Click here.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain Therapy 52

FloridaMarijuana.net

JUNE 19, 2018

Sometimes traditional veterinary pharmaceuticals may not always be effective for dogs and cats and the side-effects may interfere with a pet’s quality of life. CBD (cannabidiol) is the non-psychoactive ingredient in cannabis. CBD does not contribute to an intoxicating feeling as is prevalent with other cannabis use.

Pets 186

Pets CBD Tincture Oil 186

Veriheal

AUGUST 9, 2023

In the new yet-to-be-published study, researchers led by Rodrigo Moura Neto, a Molecular Biologist at the Federal University of Rio de Janeiro, discovered a CBD-like compound in Trema micrantha, a common plant in Brazil. Presently, CBD is inarguably the most acceptable compound in cannabis.

CBD 94

CBD Cannabinoids THC Extraction 94

Cannabis Law Report

JULY 21, 2019

FWB: 8K51)(OTC: WLDCF) (the “Company” or “ ICC ” or “ International Cannabis”) is pleased to announce that the Company has entered into an exclusive supply and commercial rights agreement (the “Agreement”) with licensed New Zealand medical cannabis company, NUBU Pharmaceuticals (“NUBU”). (CSE: WRLD.U)(FWB:

Pharmaceutical 40

Pharmaceutical THC CBD Supply Chain 40

Cannabis Law Report

JULY 19, 2019

FWB: 8K51)(OTC: WLDCF) (the “Company” or “ ICC ” or “ International Cannabis”) is pleased to announce that the Company has entered into an exclusive supply and commercial rights agreement (the “Agreement”) with licensed New Zealand medical cannabis company, NUBU Pharmaceuticals (“NUBU”). (CSE: WRLD.U)(FWB:

Pharmaceutical 40

Pharmaceutical THC CBD Supply Chain 40

Leafwell

DECEMBER 24, 2021

For generations, people have relied on pharmaceuticals like acetaminophen, ibuprofen or even something as dangerous and addictive as prescription opioids. An important and often overlooked part of that medicinal cannabis family is cannabidiol oil or CBD oil for short. CBD oil offers a range of benefits.

Oil 73

Oil CBD Pharmaceutical Medicine 73

Cannabis Law Report

JUNE 17, 2021

NASDAQ: CLVR) said it has entered into an active pharmaceutical ingredient supply agreement with CBD Life Holding SAPI de CV, an emerging leader in the Mexican cannabis industry which offers a line of CBD Wellness and consumer products and medical cannabis products which are under development. Clever Leaves Holdings Inc.

CBD 111

CBD Pharmaceutical Compliance Compliance 111

Cannabis Law Report

AUGUST 12, 2022

– August 11, 2022) – MOTAGON, a pharmaceutical company based in Prague and specializing in medical cannabis, has secured a ground-breaking agreement with Europe’s biggest indoor cannabis producer and one of the first cannabis extracts and formulations producers PHCANN INTERNATIONAL.

Extraction 52

Extraction Pharmaceutical Patients THC 52

Cannabis Law Report

AUGUST 6, 2021

CBD, which is an abbreviation for Cannabidiol, is one of Cannabis’s primary components – one of its primary Cannabinoids. CBD does not give its users the ‘high’ typically associated with Cannabis. In this article, we’ll tell you what some of the top health benefits of CBD products are: Mental Health Disorders. Analgesic Effects.

CBD 105

CBD Wellness and Beauty Treatment Pharmaceutical 105

Cannabis Law Report

AUGUST 20, 2021

Although studies have shown that CBD can be beneficial for improving conditions like spasms, anxiety disorders, and pains, there are still several grey areas that the researchers are trying to figure out. However, veterinary studies have shown that CBD can be beneficial for relieving the same symptoms in animals like cats and dogs.

CBD 105

CBD Pets Pharmaceutical Conditions 105

Cannabis Law Report

SEPTEMBER 1, 2021

CBD Capital CEO, Hassan Akhtar, will continue to serve in his current role. CBD Capital also brings with it several sub-brands that will now enjoy accelerated product development and market expansion as more resources are devoted to them. This is the GenCanna way.”.

CBD 102

CBD Supply Chain Compliance Compliance 102

Cannabis Law Report

AUGUST 17, 2021

SEATTLE–(BUSINESS WIRE)–Receptor Life Sciences (RLS), a pharmaceutical company developing innovative therapies to address central nervous system disorders, announced the publication of a manuscript in the Journal of Pharmaceutical Sciences. RLS103 delivered CBD with an efficiency 7-fold greater than a vaporizer.

CBD 98

CBD Research and Development Pharmaceutical Therapy 98

Leafwell

DECEMBER 4, 2020

One of the greatest promises of medical cannabis is the hope that cannabidiol (CBD) products extend to people suffering from anxiety. CBD products are perceived as a safer, less toxic option to pharmaceutical chemicals in treating conditions related to anxiety disorders.

CBD 60

CBD Pharmaceutical Conditions Cannabis 60

Medical Marijuana Program Connection

APRIL 17, 2024

Wolfgang Claussen from Pixabay Chronic pain adversely affects the quality of life of millions of people, and current pharmaceutical treatment options for it remain limited. Acetaminophen can damage liver function and is largely ineffective for arthritis.

Chronic Pain 40

Chronic Pain Pharmaceutical CBD Treatment 40

Cannabis Law Report

AUGUST 29, 2021

This shipment also marks the 11 th country to which SMGH has exported the Aureus™ branded products, which include a range of CBD, THC and CBG extracts and feminized seeds. NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. About Avicanna.

Extraction 98

Extraction Supply Chain Research and Development CBD 98

Puff Puff Post

MARCH 10, 2020

SOURCE InMed Pharmaceuticals Inc. About InMed: InMed Pharmaceuticals is a clinical stage pharmaceutical company developing a pipeline of cannabinoid-based medications, initially focused on the therapeutic benefits of cannabinol (CBN) in diseases with high unmet medical need.

Clinical Trials 84

Clinical Trials Pharmaceutical Research and Development Cannabinoids 84

Canna Law Blog

JANUARY 11, 2023

However, Google recently has decided to relax its advertising policies– at least around hemp and hemp CBD products. CBD advertising changes at Google. or less in California, Colorado, and Puerto Rico” Additionally, CBD will be removed from Google’s Unapproved Pharmaceuticals and Supplements List.

Policy 69

Policy CBD Supply Chain Compliance 69